Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer: a phase 3 randomized controlled trial (NATALEE)

作者
Hope S. Rugo,Nadia Harbeck,Gabriel N. Hortobágyi,Joyce O’Shaughnessy,C.-S. Huang,M. Martin,Dejan Juric,B. Pistilli,Bingge Xu,Michelino De Laurentiis,Michael Untch,Karen Afenjar,M. Gao,Z. Li,N. Bolotova,S. Waters,C. Barrios
出处
期刊:Breast Cancer Research [BioMed Central]
卷期号:28 (1) 被引量:1
标识
DOI:10.1186/s13058-026-02352-2
摘要

BACKGROUND: The phase 3 NATALEE trial demonstrated sustained invasive disease-free survival benefit for patients with stage II or III HR+/HER2- early breast cancer (EBC) treated with ribociclib + nonsteroidal aromatase inhibitor (NSAI) vs. NSAI alone. Here we report detailed safety and tolerability data from NATALEE to further inform clinical decision-making. METHODS: In NATALEE, men and pre- and postmenopausal women with HR+/HER2- EBC were randomized 1:1 to ribociclib 400 mg/day (3 weeks on/1 week off; 36 months) + NSAI (anastrozole or letrozole; ≥60 months) or NSAI alone. Men and premenopausal women also received goserelin. Safety analyses included incidence of treatment-emergent adverse events (AEs) as well as severity, timing, management, and outcomes. Safety parameters among older vs. younger patients were also assessed. RESULTS: At this 45.7-month median follow-up (data cutoff: April 29, 2024), the safety analysis set comprised 4967 patients receiving ribociclib + NSAI (n = 2526) or NSAI alone (n = 2441). The most common grade ≥ 3 AEs occurring with ribociclib + NSAI vs. NSAI alone, respectively, were neutropenia (grouped term; 44.4% vs. 0.9%), liver-related AEs (grouped term; 8.6% vs. 1.7%), and leukopenia (grouped term; 8.0% vs. 0.4%). Drug-related serious AEs occurred in 2.8% vs. 0.5%, respectively. Among patients receiving ribociclib + NSAI, AE-related ribociclib discontinuation occurred in 20.2% (median onset, 4.3 months), with 9.0% of instances occurring because of liver-related AEs. AE-related ribociclib dose interruptions (66.8%; median onset, 1.8 months) and dose reductions (23.0%; median onset, 3.2 months) were primarily driven by neutropenia (dose interruptions, 43.4%; dose reductions, 14.1%). In the ribociclib + NSAI arm, AE incidence and ribociclib dose interruptions or reductions occurred at similar rates among older patients (≥ 65 years) and younger patients (< 65 years). A higher proportion of older patients permanently discontinued ribociclib due to AEs (28.1%; n = 113/402) vs. younger patients (18.6%; n = 396/2124), most commonly due to alanine aminotransferase increased (older, 8.5%; younger, 7.0%). CONCLUSIONS: Overall, ribociclib 400 mg was well tolerated, including in older patients, and AEs were manageable with current NATALEE label recommendations of dose interruptions and reductions. Trial registration ClinicalTrials.gov identifier: NCT03701334 (registered September 21, 2018).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
打打的应助被机智小夏采纳,获得10
1秒前
2秒前
鳗鱼铭发布了新的文献求助10
2秒前
科目三的应助被枫丶采纳,获得10
2秒前
加速度完成签到,获得积分10
2秒前
RosecLuo完成签到 ,获得积分10
2秒前
帅狗发布了新的文献求助10
3秒前
情怀的应助被芙氟采纳,获得10
3秒前
4秒前
hkp发布了新的文献求助10
5秒前
淳之风完成签到,获得积分10
5秒前
6秒前
7秒前
lll完成签到,获得积分10
8秒前
JamesPei的应助被天蓬猪大帅采纳,获得10
8秒前
Nole的应助被平淡雪瑶采纳,获得10
8秒前
CipherSage的应助被41651653采纳,获得10
8秒前
无花果的应助被轻松的迎曼采纳,获得10
9秒前
ming发布了新的文献求助10
10秒前
10秒前
10秒前
lil完成签到,获得积分10
10秒前
Mr.egg发布了新的文献求助10
10秒前
云与客发布了新的文献求助10
11秒前
LUO111完成签到,获得积分10
11秒前
00hello00发布了新的文献求助10
11秒前
11秒前
FashionBoy的应助被QQ采纳,获得10
12秒前
大院的鸭完成签到,获得积分10
12秒前
科研通AI6.3的应助被zcw采纳,获得10
12秒前
13秒前
搜集达人的应助被水煮鱼采纳,获得10
13秒前
隐形曼青的应助被任伟超采纳,获得10
13秒前
权瑞松发布了新的文献求助30
15秒前
孙昌耀完成签到,获得积分10
15秒前
zhanghang完成签到,获得积分10
15秒前
lll发布了新的文献求助30
16秒前
简简单单完成签到,获得积分10
17秒前
孔原完成签到 ,获得积分20
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193335
求助须知:如何正确求助?哪些是违规求助? 9579489
关于积分的说明 21865844
捐赠科研通 7792843
什么是DOI,文献DOI怎么找? 3437210
关于科研通互助平台的介绍 2560687
邀请新用户注册赠送积分活动 2483996